News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
恒瑞醫藥(01276.HK)瑞康曲妥珠單抗獲納入突破性治療品種名單
恒瑞醫藥(01276.HK)公布，子公司蘇州盛迪亞的注射用瑞康曲妥珠單抗(SHR-A1811)獲國家藥品監督管理局藥品審評中心納入突破性治療品種名單，擬定適應症為聯合帕妥珠單抗用於人表皮生長因子受體2(HER2)陽性的復發或轉移性乳腺癌患者，針對復發/轉移性疾病，患者既往應未接受過抗HER2治療。這是瑞康曲妥珠單抗第11項獲得突破性治療認證的適應症。(de/...
Reset
Send
The window will close in 5 seconds
恒瑞醫藥(01276.HK)瑞康曲妥珠單抗獲納入突破性治療品種名單
Close
Recommend
4
Positive
5
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

恒瑞醫藥(01276.HK)  -1.700 (-2.824%)    Short selling $25.08M; Ratio 12.314%   公布，子公司蘇州盛迪亞的注射用瑞康曲妥珠單抗(SHR-A1811)獲國家藥品監督管理局藥品審評中心納入突破性治療品種名單，擬定適應症為聯合帕妥珠單抗用於人表皮生長因子受體2(HER2)陽性的復發或轉移性乳腺癌患者，針對復發/轉移性疾病，患者既往應未接受過抗HER2治療。這是瑞康曲妥珠單抗第11項獲得突破性治療認證的適應症。(de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-01 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.